The answer is medically unsound, however, because weight loss efficacy does not scale linearly with medication count
However, current data are inconsistent and inconclusive, possibly because of the variety of protocols that were utilized (such as meal tolerance versus glucose tolerance, different abnormal sleep patterns, and timing of GLP-sampling) and the heterogenous populations enrolled in the above studies [4452]
It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication
doi: 10.1159/000371851 153 DoknicMPekicSZarkovicMMedic-StojanoskaMDieguezCCasanuevaFet al
